BACKGROUND Anticoagulation for chronic dialysis patients with contraindications to heparin administration is challenging. Current guidelines state that in patients with increased bleeding risks, strategies that can induce systemic anticoagulation should be avoided. Heparin-free dialysis using intermittent saline flushes is widely adopted as the method of choice for patients at risk of bleeding,...

The utilization of mechanical life support due to respiratory insufficiency and serious cardiac pathologies have been increasing. Anticoagulation to prevent clot formation is mandatory and unfractioned heparin is the standard therapy in use. But rarely heparin induced thrombocytopenia (HIT) might develop as an immunologic side effect of heparin. Development of thrombosis as a result of HIT incr...

nitroglycerin has been reported to reduce activated partial thromboplastin time (aptt) values in patients treated with concurrent heparin and nitroglycerin. however, studies have yielded conflicting results. to determine whether intravenous nitroglycerin alters the anticoagulant effect of heparin, we prospectively evaluated twenty patients admitted for coronary angioplasty by measuring their ap...

BACKGROUND Low-molecular-weight heparin (LMWH) has been suggested as providing safe, efficient, convenient and possibly more cost-effective anticoagulation for haemodialysis (HD) than unfractionated heparin, with fewer side-effects and possible benefits on uraemic dyslipidaemia. METHODS In this prospective, randomized, cross-over study we compared the safety, clinical efficacy and cost effect...

The ability of heparin to dramatically enhance the inactivation of thrombin (IIa) by antithrombin III (ATIII) in buffer is negated through formation of a IIa-fibrin-heparin ternary complex (Hogg and Jackson, Proc Natl Acad Sci USA 86:3619, 1989; Hogg and Jackson, J Biol Chem 265:241, 1990). IIa, in this ternary complex, is protected from inactivation by ATIII. Our aim was to determine whether f...

Division of Nephrology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan* Division of Nephrology, Chung Shan Medical University Hospital, Taichung, Taiwan** Department of Biotechnology, Hung Kuang University***, Department of Life Science, Tunghai University**** Received: July, 2004 Revised: April, 2005 Accepted: June, 2005 Address reprint requests to Dr. Ku...

heparin is frequently used in different clinical settings to reduce the coagulating ability of the blood. because of probable adverse effects owing to heparin therapy and regarding variability of patients’ responses to heparin, which make it very unreliable, it seems prudent to monitor meticulously its effects on the human body. there are a lot of laboratory tests to watch its effects on the bo...

OBJECTIVE To determine whether an intravenous heparin dosing nomogram based on body weight achieves therapeutic anticoagulation more rapidly than a "standard care" nomogram. DESIGN Randomized controlled trial. SETTING Two community teaching hospitals in Phoenix, Arizona, and Rochester, New York. PARTICIPANTS One hundred fifteen patients requiring intravenous heparin treatment for venous o...

The specificity of endothelial binding sites for heparin was investigated with heparin fractions and fragments differing in their Mr, charge density and affinity for antithrombin III, as well as with heparinoids and other anionic polyelectrolytes (polystyrene sulphonates). The affinity for endothelial cells was estimated by determining I50 values in competition experiments with 125I-heparin. We...

Stents rarely thrombose in the first 24 hours after implantation; secondly, heparin has some influence on the extrinsic pathway. Additionally, if too much heparin is present it interferes with the INR, and the half life of prothrombin suggests that the patient should be anticoagulated with heparin for up to 96 hours after starting warfarin. This is the evidence on which our standard protocol is...